{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:04:21Z","timestamp":1781510661542,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jhep.2013.08.005","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T16:07:00Z","timestamp":1376669220000},"page":"1278-1284","source":"Crossref","is-referenced-by-count":85,"title":["FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis"],"prefix":"10.1016","volume":"59","author":[{"given":"Andreas","family":"Wannhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Roksund","family":"Hov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Folseraas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarl Andreas","family":"Anmarkrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Heinz","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten Muri","family":"Boberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Stremmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Hemming","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Nils","family":"Gotthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.08.005_b0005","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.08.005_b0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"Bergquist","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.08.005_b0015","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.24570","article-title":"Cancer surveillance in patients with primary sclerosing cholangitis","volume":"54","author":"Razumilava","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.08.005_b0020","first-page":"512","article-title":"Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients","volume":"58","author":"Narimatsu","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2013.08.005_b0025","doi-asserted-by":"crossref","first-page":"29271","DOI":"10.1016\/S0021-9258(19)62041-7","article-title":"Molecular genetic analysis of the human Lewis histo-blood group system","volume":"269","author":"Nishihara","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2013.08.005_b0030","first-page":"5489","article-title":"Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin","volume":"43","author":"Magnani","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2013.08.005_b0035","doi-asserted-by":"crossref","first-page":"20987","DOI":"10.1016\/S0021-9258(17)31919-1","article-title":"Molecular basis for Lewis alpha(1,3\/1,4)-fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian pedigrees","volume":"269","author":"Mollicone","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2013.08.005_b0040","first-page":"241","article-title":"MALDI-TOF mass spectrometry-based SNP genotyping","volume":"212","author":"Storm","year":"2003","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhep.2013.08.005_b0045","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00277-002-0508-x","article-title":"Distribution of Lewis (FUT3)genotype and allele: frequencies in a biethnic United States population","volume":"81","author":"Cakir","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jhep.2013.08.005_b0050","doi-asserted-by":"crossref","first-page":"21994","DOI":"10.1074\/jbc.272.35.21994","article-title":"Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human alpha(1,3\/1,4)-fucosyltransferase","volume":"272","author":"Elmgren","year":"1997","journal-title":"Fuc-TIII. J Biol Chem"},{"key":"10.1016\/j.jhep.2013.08.005_b0055","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1074\/jbc.270.9.4640","article-title":"Sequence and expression of a candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype","volume":"270","author":"Kelly","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2013.08.005_b0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/glycob\/9.4.373","article-title":"Molecular behavior of mutant Lewis enzymes in vivo","volume":"9","author":"Nishihara","year":"1999","journal-title":"Glycobiology"},{"key":"10.1016\/j.jhep.2013.08.005_b0065","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2796.2000.00682.x","article-title":"Genetic background of Lewis negative blood group phenotype and its association with atherosclerotic disease in the NHLBI family heart study","volume":"247","author":"Salomaa","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.jhep.2013.08.005_b0070","doi-asserted-by":"crossref","first-page":"32260","DOI":"10.1074\/jbc.271.50.32260","article-title":"Influence of Lewis alpha1-3\/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels","volume":"271","author":"Orntoft","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2013.08.005_b0075","first-page":"54","article-title":"Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population","volume":"45","author":"Vestergaard","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.jhep.2013.08.005_b0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4318\/tjg.2011.0186","article-title":"Relationship of CA 19-9 with choledocholithiasis and cholangitis","volume":"22","author":"Dogan","year":"2011","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.08.005_b0085","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","article-title":"The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis","volume":"50","author":"Levy","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2013.08.005_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.510310103","article-title":"Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study","volume":"31","author":"Chalasani","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.08.005_b0095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","article-title":"Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma","volume":"242","author":"Rea","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2013.08.005_b0100","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.22441","article-title":"Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis","volume":"48","author":"Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.08.005_b0105","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/jnci\/89.19.1440","article-title":"Fecal occult blood screening in the Minnesota study: sensitivity of the screening test","volume":"89","author":"Church","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2013.08.005_b0110","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/j.cgh.2011.02.007","article-title":"Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma","volume":"9","author":"Sinakos","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.08.005_b0115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jhep.2012.03.031","article-title":"Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci","volume":"57","author":"Folseraas","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.08.005_b0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the Liver","year":"2009","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813005588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813005588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:31:44Z","timestamp":1646353904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827813005588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0168827813005588"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.08.005","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}